Questcor Pharmaceuticals, Inc. (AMEX:QSC) announced today that
its board of directors has approved the decision to switch the listing
of its common stock from the American Stock Exchange to the NASDAQ Stock
Market LLC. Effective May 16, 2008 the Company’s
trading symbol will change from QSC to the new symbol QCOR.
“The decision to move was made after careful
consideration of the capital market alternatives and input from current
shareholders,” said Don Bailey, President and
Chief Executive Officer of Questcor Pharmaceuticals. “We
feel that this move and symbol change to QCOR will provide added
visibility to our investors as well as enhanced exposure and liquidity
for our company. NASDAQ represents the future as the world’s
largest exchange and we are happy to be a part of it.”
About NASDAQ
NASDAQ is the largest U.S. electronic stock market. With approximately
3200 companies, it lists more companies and, on average, its systems
trade more shares per day than any other U.S. market. NASDAQ is home to
companies that are leaders across all areas of business including
technology, retail, communications, financial services, transportation,
media and biotechnology. NASDAQ is the primary market for trading
NASDAQ-listed stocks. For more information about NASDAQ, visit the
NASDAQ website at http://www.nasdaq.com
or the NASDAQ newsroom at http://www.nasdaq.com/newsroom.
About Questcor
Questcor Pharmaceuticals, Inc. is a pharmaceutical company that owns two
commercial products, H.P. Acthar® Gel (“Acthar”)
and Doral®, and is developing new medications
using strategies that generally require lower capital investment when
compared to traditional development programs. Acthar (repository
corticotropin injection) is an injectable drug that is approved for the
treatment of certain disorders with an inflammatory component, including
the treatment of exacerbations associated with multiple sclerosis (“MS”).
In addition, Acthar is not indicated for, but is used in treating
patients with infantile spasms (“IS”),
a rare form of refractory childhood epilepsy, and opsoclonus myoclonus
syndrome, a rare autoimmune-related childhood neurological disorder.
Doral is indicated for the treatment of insomnia characterized by
difficulty in falling asleep, frequent nocturnal awakenings, and/or
early morning awakenings. The Company is also developing new
medications, including QSC-001, a unique orally disintegrating tablet
formulation of hydrocodone bitartrate and acetaminophen for the
treatment of moderate to moderately severe pain. For more information,
please visit www.questcor.com.
|